The Oncology Institute, Inc.

NASDAQ:TOI

0.8823 (USD) • At close February 4, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12018 Q4
Revenue 99.90198.57894.66685.78882.03580.22476.19271.42464.97760.92155.16152.30452.27549.84348.58187.51547.24947.2844.0237.359
Cost of Revenue 85.53585.55284.18672.98666.05765.10762.09355.79551.97749.77942.83943.97140.85238.95438.37866.72337.67637.79137.04628.931
Gross Profit 14.36613.02610.4812.80215.97815.11714.09915.6291311.14212.3228.33311.42310.88910.202120.7929.5739.4886.9748.428
Gross Profit Ratio 0.1440.1320.1110.1490.1950.1880.1850.2190.20.1830.2230.1590.2190.2180.210.6440.2030.2010.1580.226
Reseach & Development Expenses 00000000000000000000
General & Administrative Expenses 000000000001.5251.5252.5330.1350.1480.1480.1450.0380
Selling & Marketing Expenses 0000000000046.7211.2058.67911.04341.41808.4038.7840
SG&A 26.64627.87228.45228.08828.20528.72628.8329.57231.96328.34829.80648.24512.7311.21211.17841.5660.1488.5478.8228.833
Other Expenses 1.5731.5180.068-0.35-0.14-0.3571.2691.1921.1341.0980.987-0.080.054-0.0041.0763.0280.051.01800.764
Operating Expenses 28.21929.3928.45228.08829.90330.05530.09930.76433.09729.44630.79349.16413.5812.00611.95544.5940.1989.34817.0839.598
Operating Income -13.853-16.364-17.972-15.286-13.925-14.938-16-15.135-20.097-18.304-18.471-40.831-2.157-1.117-1.753-7.715-0.1980.14-2.643-1.17
Operating Income Ratio -0.139-0.166-0.19-0.178-0.17-0.186-0.21-0.212-0.309-0.3-0.335-0.781-0.041-0.022-0.036-0.041-0.0040.003-0.06-0.031
Total Other Income Expenses Net -2.260.885-1.917-3.78-3.359-1.862.91313.70517.39912.81937.93728.208-0.0245.1010.975-3.06-2.2060.908-7.507-0.002
Income Before Tax -16.113-15.479-19.889-18.841-17.284-16.798-29.954-9.379-2.698-5.48519.466-12.623-2.1813.984-0.778-9.014-2.4041.047-10.15-1.171
Income Before Tax Ratio -0.161-0.157-0.21-0.22-0.211-0.209-0.393-0.131-0.042-0.090.353-0.241-0.0420.08-0.016-0.048-0.0510.022-0.231-0.031
Income Tax Expense 00-3.617-0.0870.1350.0990.0440.123-0.024-0.0320.18-2.4670.7990.780.218-0.5050.0130.0290.3040.822
Net Income -16.113-15.479-16.272-15.314-17.419-16.897-29.998-9.502-2.674-5.45315.767-10.156-2.983.205-0.996-8.509-2.4171.018-9.846-1.994
Net Income Ratio -0.161-0.157-0.172-0.179-0.212-0.211-0.394-0.133-0.041-0.090.286-0.194-0.0570.064-0.021-0.045-0.0510.022-0.224-0.053
EPS -0.18-0.17-0.22-0.21-0.24-0.23-0.41-0.13-0.034-0.0750.22-0.15-0.040.05-0.015-0.3-0.0840.015-0.43-0.03
EPS Diluted -0.18-0.17-0.22-0.21-0.24-0.23-0.41-0.11-0.034-0.0750.21-0.15-0.040.05-0.015-0.3-0.0840.015-1.71-0.03
EBITDA -12.315-14.846-16.415-20.009-12.891-13.554-26.035-5.737-0.067-4.326-15.964-11.644-1.576-0.326-0.237-8.043-0.1980.941-1.848-0.405
EBITDA Ratio -0.123-0.151-0.174-0.16-0.139-0.161-0.176-0.186-0.292-0.282-0.32-0.765-0.024-0.0070.002-0.0750.0440.041-0.042-0.011